Adipose-derived mesenchymal stem cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling

Oncotarget

Volumn 5, Issue 3, 2014, Pages 613-633

  Eterno, Vincenzo ^a   Zambelli, Alberto ^a   Pavesi, Lorenzo ^a   Villani, Laura ^a   Zanini, Vittorio ^a   Petrolo, Gianfranco ^a   Manera, Stefania ^a   Tuscano, Antonella ^a   Amato, Angela ^a  

^a IRCCS   (Italy)

Author keywords

Adipose derived mesenchymal stem cells (ASCs); Breast cancer; HGF c met crosstalk; Microenvironment; Neoangiogenesis

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; HERMES ANTIGEN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; THY 1 ANTIGEN; HGF PROTEIN, HUMAN; MET PROTEIN, HUMAN;

ADIPOSE DERIVED STEM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RECURRENCE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MULTIPOTENT STEM CELL; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; ADIPOSE TISSUE; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL DIFFERENTIATION; CELL GROWTH; FEMALE; MESENCHYMAL STROMA CELL; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE; TUMOR RECURRENCE; XENOGRAFT;

ADIPOSE TISSUE; ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; FEMALE; HEPATOCYTE GROWTH FACTOR; HETEROGRAFTS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84896815812     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1359     Document Type: Article

References (63)

1. Zuk, P.A. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001; 7(2):211-28.
2. Sémont A, François S, Mouiseddine M, François A, Saché A, Frick J, Thierry D, Chapel A. Mesenchymal stem cells increase self-renewal of small intestinal epithelium and accelerate structural recovery after radiation injury. Adv Exp Med Biol. 2006; 585:19-30.
3. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009; 23(22):2563-2577.
4. Karnoub AE and Weinberg RA. Chemokine Networks and Breast Cancer Metastasis Breast Disease. 2006; 26:75-85.
5. Yu JL, Rak JW. Inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Canc Res. 2002; 5:83-88.
6. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410:50-56.
7. Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 357:539-545.
8. Chandler EM, Seo BR, Califano JP, Andresen Eguiluz RC, Lee JS, Yoon CJ, Tims DT, Wang JX, Cheng L, Mohanan S, Buckley MR, Cohen I, Nikitin AY, Williams RM, Gourdon D, Reinhart-King CA, Fischbach C. Implanted adipose progenitor cells as physicochemical regulators of breast cancer. Proc Natl Acad Sci. U S A. 2012; 109(25):9786-9791.
9. Liotta LA, Kohn EC. The microenvironment of the tumor host interface Nature. 2001; 411: 375-379.
10. Lazennec G and Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010; 16(3):133-144.
11. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121(3):335-48.
12. Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol. 2006; 195(4):173-83.
13. Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, Zhu YF, Wang SM. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer. 2007; 121(9):1949-57.
14. Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, Zhu YF, Wang SM. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer. 2007; 121(9):1949-57.
15. LeBedis C, Chen K, Fallavollita L, Boutros T, Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int J Cancer. 2002; 100(1):2-8.
16. Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A, Sgarra R, Del Sal G, Manfioletti G: HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget. 2013; 4(8):1293-308.
17. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal Stem Cells within tumor stroma promote breast cancer metastasis. Nature; 2007; 449(7162):557-563.
18. Martin FT, Dwyer RM, Kelly J, Khan S, Murphy JM, Curran C, Miller N, Hennessy E, Dockery P, Barry FP, O'Brien T, Kerin MJ. Potential role of mesenchymal stem cells (MSCs) in the breast tumor microenvironment:stimulation of epithelial to mesenchymal transition (EMT). Breast Canc Res Treat. 2010; 124(2):317-326.
19. Zhao M, Sachs PC, Wang X, Dumur CI, Idowu MO, Robila V, Francis MP, Ware J, Beckman M, Rizki A, Holt SE, Elmore LW. Mesenchymal stem cells in mammary adipose tissue stimulate progression of breast cancer resembling the basal-type. Cancer Biol Ther. 2012; 13(9):782-92.
20. Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, Jasmin JF, Schwarting R, Pestell RG, Blagosklonny MV, Lisanti MP. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drg. Am J Pathol. 2012; 181(1):278-93.
21. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. U S A. 2003; 100(7):3983-8.
22. Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, Spaeth E, Xu W, Zhang X, Lewis MT, Reuben JM, Krishnamurthy S, Ferrari M, Gaspar R, Buchholz TA, Cristofanilli M, Marini F, Andreeff M, Woodward WA. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One. 2010; 5(8):e12180
23. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, Wicha MS. Breast cancer stem cells are regulated by mesenchymal stem cells trough cytokine networks. Cancer Res. 2011; 71(2):614-624
24. Dale TC, Weber-Hall SJ, Smith K, Huguet EL, Jayatilake H, Gusterson BA, Shuttleworth G, O'Hare M, Harris AL. Compartment switching of WNT-2 expression in human breast tumors. Cancer Res. 1996; 56(19):4320-3.
25. Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget. 2010; 1(7):552-66.
26. Junttila MR, de Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature. 2013; 501(7467):346-54.
27. Fang H, Declerck YA.Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 2013; 73(16):4965-77.
28. Sun B, Roh KH, Park JR, Lee SR, Park SB, Jung JW et al. Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy. 2009; 11(3): 289-98, 1p following 298.
29. Donnenberg VS, Zimmerlin L, Rubin JP, Donnenberg AD. Regenerative therapy after Cancer: What are the risks? Tissue Eng Part B Rev. 2010; 16(6):567-575.
30. Pearl RA, Leedham SJ, Pacifico MD. The safety of autologous fat transfer in breast cancer: Lessons from stem cell biology. J Plast Reconstr Aesthet Surg. 2012; 65(3):283-8.
31. Chaput B, Foucras L, Guellec JL, Garrido I. Recurrence of an invasive ductal breast carcinoma 4 months after autologous fat grafting. Plast Reconstr Surg. 2013; 131(1):123e-4e.
32. Perrot P, Rousseau J, Bouffaut AL, Rédini F, Cassagnau E, Deschaseaux F, Heymann MF, Heymann D, Duteille F, Trichet V, Gouin F. Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One. 2010; 5(6):e10999.
33. Zimmerlin L, Donnenberg VS, Donnenberg AD. Rare event detection and analysis in flow cytometry: bone marrow mesenchymal stem cells, breast cancer stem/progenitor cells in malignant effusions, and pericytes in disaggregated adipose tissue. Methods Mol Biol. 2011; 13(4):441-448.
34. Brooks B, Bundred NJ, Howell A, Lang SH, Testa NG. Investigation of mammary epithelial cell-bone marrow stroma interactions using primary human culture as model of metastasis. Int. J Cancer. 1997; 73:690-696.
35. Yoshimura, K. et al. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J Cell Physiol. 2006; 208(1):64-76.
36. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop DJ, Horwitz E. Minimal Criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315.317.
37. Tran DD, Corsa CA, Biswas H, Aft RL, Longmore GD. Temporal and Spatial cooperation of Snail1 and Twist1 during Epithelial-to-mesenchymal transition Predicts for human breast cancer recurrence. Mol Cancer Res. 2011; 9(12):1644-1657.
38. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci. U S A. 2010; 107(35):15449-15454.
39. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer. 1998; 82(8):1513-20.
40. Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M, Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004; 22(3):377-84.
41. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010; 468 (7325):829-33.
42. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11.
43. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986; 315(26):1650-9.
44. Yant J, Buluwela L, Niranjan B, Gusterson B, Kamalati T. In vivo effects of hepatocyte growth factor/scatter factor on mouse mammary gland development. Exp Cell Res. 1998; 241(2):476-81.
45. Mazzone M, Comoglio PM.The Met pathway: master switch and drug target in cancer progression. FASEB J. 2006; 20(10):1611-21.
46. Benjamin LE, Hemo I, Kesher E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the performed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998; 125(9):1591-8.
47. Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget.2011; 2(7):538-50.
48. Reikvam H, Nepstad I, Bruserud Ø, Hatfield KJ. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget.2013; 4(6):830-43.
49. Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem. 2003; 88(2):408-417.
50. Howe LR, Watanabe O, Leonard J, Brown AM. Twist is upregulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res. 2003; 63(8):1906-13.
51. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12(2):89-103.
52. Kawakami H, Okamoto I, Arao T, Okamoto W, Matsumoto K, Taniguchi H, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K, Yamada Y. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget. 2013; 4(1):9-17.
53. Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C: Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008; 68(5):1471-7.
54. Yamashita, J., Ogawa, M., Yamashita, S., et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 1994; 54, 1630-1633.
55. Droujinine IA, Eckert MA, Zhao W: To grab the stroma by the horns: from biology to cancer therapy with mesenchymal stem cells. Oncotarget. 2013; 4(5):651-64.
56. Prud'homme GJ, Glinka Y: Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget. 2012; 3(9):921-39.
57. Delay E, Garson S, Tousson G, Sinna R. Fat injection to the breast: technique, results, and indications based on 880 procedures over 10 years. Aesthet Surg J. 2009; 29(5):360-76.
58. Illouz YG, Sterodimas A. Autologous fat transplantation to the breast: a personal technique with 25 years of experience. Aesthetic Plast Surg. 2009; 33(5):706-15.
59. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature, 2000; 406(6797):747-52.
60. Moore MM, Borossa G, Imbrie JZ, Fechner RE, Harvey JA, Slingluff CL Jr, Adams RB, Hanks JB. Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy. Ann Surg. 2000; 231(6):877-82.
61. Mascaro A, Farina M, Gigli R, Vitelli CE, Fortunato L. Farante. Recent advances in the surgical care of breast cancer patients. World J Surg Oncol. 2010; 8:5.
62. Farante G, Zurrida S, Galimberti V, Veronesi P, Curigliano G, Luini A, Goldhirsch A, Veronesi U. The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy. Breast Cancer Res Treat. 2011; 128(2):369-78.
63. Amato A, Schillaci T, Lentini L, Di Leonardo A. CENPA overexpression promotes genome instability in pRbdepleted human cells. Mol Cancer. 2009; 8:119.